Cosela is owned by G1 Therap.
Cosela contains Trilaciclib Dihydrochloride.
Cosela has a total of 10 drug patents out of which 0 drug patents have expired.
Cosela was authorised for market use on 12 February, 2021.
Cosela is available in powder;intravenous dosage forms.
Cosela can be used as a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer, a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer.
Drug patent challenges can be filed against Cosela from February, 2025.
The generics of Cosela are possible to be released after 14 March, 2034.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8598186 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
US9957276 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
US10189849 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
US8598197 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10189850 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
US10927120 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
US10085992 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
US10966984 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
US11040042 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
US9487530 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: February, 2025
Market Authorisation Date: 12 February, 2021
Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer
Dosage: POWDER;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic